PuSH - Publikationsserver des Helmholtz Zentrums München

Tigu, A.B.* ; Ivancuta, A.* ; Tomuleasa, C.* ; Nistor, M.* ; Kegyes, D.* ; Cenariu, D.* ; Munteanu, R.* ; Buzoianu, A.D.* ; Einsele, H.* ; Federico, M.* ; Kobold, S. ; Gulei, D.* ; Ciechanover, A.*

Proteolysis targeting chimeric-based technology in myeloma and lymphoma.

Mol. Cancer Ther. 25, 1264-1280 (2026)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Proteolysis-targeting chimeras (PROTAC) leverage the ubiquitin-proteasome system to selectively degrade oncogenic proteins, including those previously seen as undruggable. Recent preclinical studies indicate that PROTACs may represent a novel therapeutic strategy in lymphoma and myeloma. Indeed, preclinically, PROTACs have shown high efficacy and remarkable selectivity, a favorable safety profile, and lower toxicity compared with conventional therapies. Their catalytic, reusable mechanism enables drug dosing and offers the perspective of long-term low-dose treatment. PROTACs have demonstrated their ability to overcome drug resistance by targeting and degrading overexpressed or mutant proteins that are responsible for refractory disease. This review aims to offer a comprehensive evaluation of the currently existing PROTACs that have been tested in lymphoma and myeloma to highlight the need for drug optimization and further translational research that could translate PROTACs to clinical trials.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter B-cell Lymphoma; Itk Inhibitors; Protac Design; Degradation; Pathway; Cancer; Resistance; Family; Potent; Bcl6
ISSN (print) / ISBN 1535-7163
e-ISSN 1538-8514
Zeitschrift Molecular Cancer Therapeutics
Quellenangaben Band: 25, Heft: 8, Seiten: 1264-1280 Artikelnummer: , Supplement: ,
Verlag American Association for Cancer Research (AACR)
Verlagsort 615 Chestnut St, 17th Floor, Philadelphia, Pa 19106-4404 Usa
Begutachtungsstatus Peer reviewed
Institut(e) Unit for Clinical Pharmacology (KKG-EKLiP)
Förderungen International doctoral program "i-Target: immunotargeting of cancer" - Elite Network of Bavaria
Bavarian Cancer Research Center (TANGO)
Deutsche Forschungsgemeinschaft
Melanoma Research Alliance
Marie Sklodowska-Curie Training Network for Optimizing Adoptive T-Cell Therapy of Cancer - Horizon 2020 programme of the European Union
Marie Sklodowska-Curie Training Network for tracking and controlling therapeutic immune cells in cancer - Horizon Programme of the EU
Else Kroener-Fresenius-Stiftung (IOLIN)
Israel Cancer Research Fund USA
Adelson Medical Research Foundation
Romanian Research Ministry-PNRR
European Commission - Horizon Europe Framework Network
HORIZON-TMA-MSCA-DN
Romania
Moldova
Israel Science Foundation (ISF)
ISF
German Cancer Aid (AvantCAR.de)
Wilhelm-Sander-Stiftung
Ernst Jung Stiftung
Fritz-Bender Foundation
Deutsche Jose Carreras Leukaemie Stiftung
Hector Foundation
Bavarian Research Foundation (BAYCELLator)
Monika Kutzner Foundation
Bruno and Helene Joester Foundation (360degrees CAR)
Dr. Rurainski Foundation
Brigitte
SFB-TRR
European Research Council
Institutional Strategy LMUexcellent of LMU Munich
Go-Bio Initiative
The m4-Award of the Bavarian Ministry for Economic Affairs, Bundesministerium fuor Bildung und Forschung
EUROSTAR-Programm
Dr. Konstanze Wegener Foundation